Apr 15 |
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
|
Apr 10 |
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
|
Apr 2 |
AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript
|
Apr 2 |
AIM ImmunoTech GAAP EPS of -$0.60, revenue of $0.2M
|
Apr 2 |
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Apr 2 |
Earnings Scheduled For April 2, 2024
|
Apr 1 |
AIM ImmunoTech FY 2023 Earnings Preview
|
Mar 26 |
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
|
Mar 25 |
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|
Mar 25 |
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
|